With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
  • Patent number: 11266636
    Abstract: The present invention relates to the field of anti-viral active agents, particularly to salts, more particularly to a maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, to pharmaceutical formulations thereof as well as to methods for the production of these salts. The present invention also relates to the use of theses salts and of respective pharmaceutical formulations thereof in methods of treatment and/or prevention of human herpes simplex virus infections, particularly infections caused by HSV-1 and HSV-2.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: March 8, 2022
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Yogeshwar Bachhav, Wilfried Schwab, Alexander Birkmann, Susanne Bonsmann, Thomas Goldner
  • Patent number: 11260185
    Abstract: The disclosure relates to a pressurized Metered Dose Inhaler-compatible tablet, i.e. one that is able to be dispersed or disintegrates within a liquid phase propellant, which is used in a pressurized Metered Dose Inhaler formulation containing at least one active pharmaceutical ingredient and one or more excipients.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 1, 2022
    Assignee: Cardiff Scintigraphics Limited
    Inventors: Glyn Taylor, Simon Warren, Cuong Tran
  • Patent number: 11260030
    Abstract: An oral tablet for delivery of active ingredients to the gastrointestinal tract includes a population of particles and an active ingredient to be delivered to the gastrointestinal tract. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the gastrointestinal tract as part of the saliva generated upon mastication of the tablet.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: March 1, 2022
    Assignee: Fertin Pharma A/S
    Inventor: Helle Wittorff
  • Patent number: 11241413
    Abstract: The present invention relates to a lozenge composition for controlled release of cannabinoids comprising; i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: February 8, 2022
    Inventors: Heidi Ziegler Bruun, Dorthe Schackinger Boesen, Ane Eriksen
  • Patent number: 11234962
    Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: February 1, 2022
    Assignee: FUJIFILM Toyama Chemical Co., Ltd.
    Inventors: Kotaro Okada, Yoshinori Sakata, Shigetomo Tsujihata
  • Patent number: 11213484
    Abstract: This disclosure provides orally disintegrating dipivefrin tablet (ODT) formulations, including ODT formulations containing L-dipivefrin HCl. The ODT formulations of the disclosure include 10 to 70% binder (wt %), 5 to 50% matrix former (wt %), and 1 to 20% taste masking agent (wt %). The ODT formulations of the disclosure rapidly provide epinephrine to a patient when administered. The disclosure also provides a method of treating a patient who has a condition responsive to epinephrine such as a cardiac event, asthma, croup, cancer, a microbial infection, Addison's disease, or an allergic reaction, particularly anaphylaxis by administering an orally disintegrating dipivefrin tablet formulations to the patient.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: January 4, 2022
    Assignee: INSIGNIS THERAPEUTICS, INC.
    Inventor: Mingbao Zhang
  • Patent number: 11207318
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: December 28, 2021
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 11197836
    Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: December 14, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
  • Patent number: 11154505
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising at least one organic acid; at least one drug layer comprising trihexyphenidyl or a pharmaceutically acceptable salt thereof over the core; and a functional coat over the drug-layered core. The compositions of the disclosure provide extended release with reduced Cmax, a Cmin:Cmax ratio of ?0.4, Fluctuation Index of ?1, while providing and maintaining at least a minimum therapeutically effective plasma concentration, of the trihexyphenidyl or the pharmaceutically acceptable salt thereof for at least about 10 hours. The compositions of the disclosure improve solubility of the trihexyphenidyl or the pharmaceutically acceptable salt thereof at a pH of greater than or equal to 5, to provide and maintain at least a minimum effective concentration of the drug at such pH.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: October 26, 2021
    Inventors: Namdev B. Shelke, Siva Ram Kiran- Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 11147770
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 19, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, Hongren Wang
  • Patent number: 11135188
    Abstract: A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: October 5, 2021
    Assignee: Bayer HealthCare LLC
    Inventors: Eric R. First, Ashish B. Patel, Guido Schmitz, Stephanie Petaway-Hickson, Hung-Huar Tong
  • Patent number: 11135200
    Abstract: This invention relates to the medical use of an antimicrobial agent, racemic Ornidazole, its (R) and (S) enantiomers, or pharmaceutically acceptable salts or esters thereof, and to methods of treatment which involve treating a subject with Ornidazole. The racemic (rac)-ornidazole, its enantiomers, or pharmaceutically acceptable salts or esters thereof, may be used in combination with other actives. The invention also relates to pharmaceutical formulations and compositions comprising (rac)-ornidazole, (R)-ornidazole, (S)-ornidazole, or pharmaceutically acceptable salts or esters thereof, and/or other actives as well as methods to stereoselectively manufacture the enantiomers.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: October 5, 2021
    Inventor: John Malcolm Hall Gregg
  • Patent number: 11123310
    Abstract: The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 21, 2021
    Assignees: Pharmapotheca, LLC, Chemapotheca, LLC
    Inventors: Karl Popp, Harold Meckler
  • Patent number: 11124481
    Abstract: The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 21, 2021
    Assignee: Exelixis, Inc.
    Inventors: Wei Xu, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
  • Patent number: 11096894
    Abstract: The invention relates to an oral tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 24, 2021
    Inventor: Helle Wittorff
  • Patent number: 11096895
    Abstract: The invention relates to an oral delivery tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising a) directly compressible (DC) sugar alcohol particles, b) non-directly compressible (non-DC) sugar alcohol particles and c) particles comprising gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated into a coherent residual containing water-insoluble components.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: August 24, 2021
    Inventor: Helle Wittorff
  • Patent number: 11091496
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 17, 2021
    Assignee: RHODES TECHNOLOGIES
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Patent number: 11090263
    Abstract: The invention relates to a tableted chewing gum suitable for active pharmaceutical ingredients, the chewing gum comprising a population of particles, the population of particles comprising a) directly compressible (DC) sugar alcohol particles, b) non-directly compressible (non-DC) sugar alcohol particles and c) particles comprising gum base, the gum base comprising at least 5% by weight of elastomer.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: August 17, 2021
    Assignee: FERTIN PHARMA A/S
    Inventor: Helle Wittorff
  • Patent number: 11065207
    Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: July 20, 2021
    Assignee: Universiteit Gent
    Inventors: Chris Vervaet, Jean Paul Remon, Glenn Verstraete
  • Patent number: 11058621
    Abstract: Disclosed is a product composition comprising: a discrete particle of a mixture composition, wherein the mixture composition comprises a surfactant and a high melting point fatty compound and a benefit agent; and an aqueous base composition comprising an aqueous carrier and water soluble polymer, wherein the base composition is substantially free of a detersive surfactant selected from anionic surfactants, zwitterionic surfactant, amphoteric surfactant, and combinations thereof. The product composition of the present invention provides at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; improved deposition of benefit agents; and improved visual/aesthetic appearance.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: July 13, 2021
    Assignee: The Procter and Gamble Company
    Inventors: Junichi Yokogi, XinHao Zhu, Jorge Max Sunkel
  • Patent number: 11058682
    Abstract: The present invention relates to a gastro-resistant pharmaceutical composition comprising a solid solution prepared by hot-melt extrusion, whereby the solid solution contains posaconazole, an enteric polymer and a non-enteric polymer. The composition is preferably a granulate material that can be filled into a capsule or compressed into a tablet.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 13, 2021
    Assignee: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
    Inventors: Vamshi Ramana Prathap, Venkatasimhadri Naidu Kalamata, Bala Ramesha Chary Rallabandi, Vinay Kumar Katakam, Hendrik Schlehahn
  • Patent number: 11045420
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced Cmax, a Cmin:Cmax ratio of ?0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: June 29, 2021
    Assignee: Kashiv Specialty Pharmaceuticals, LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran- Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 11040014
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced Cmax, a Cmin:Cmax ratio of ?0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 22, 2021
    Assignee: Kashiv Specialty Pharmaceuticals, LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 11033498
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: June 15, 2021
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB. Cleveland, Edmund V. Dennett, Jr., Russell W. Pelham
  • Patent number: 11020375
    Abstract: Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 1, 2021
    Assignee: SUZHOU AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Xinfu Zhou, Ankit Parikh, Sanjay Garg
  • Patent number: 11000520
    Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 11, 2021
    Assignee: Indivior UK Limited
    Inventors: Azmi Nasser, Celine M Laffont, Christian Heidbreder
  • Patent number: 10988480
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 27, 2021
    Assignee: Rhodes Technologies
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Patent number: 10966928
    Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: April 6, 2021
    Assignee: Universiteit Gent
    Inventors: Chris Vervaet, Jean Paul Remon, Glenn Verstraete
  • Patent number: 10966964
    Abstract: The present invention provides a method for preparing a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt thereof. Specifically, the invention provides a preparation method of a pharmaceutical composition, the method containing: mixing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof with at least one filler, and then granulating the mixture. The pharmaceutical composition of the invention features a rapid dissolution and good stability.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Xinhua Zhang, Chenyang Wang, Tonghui Liu
  • Patent number: 10960015
    Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 30, 2021
    Assignee: Assistance Publique-Hopitaux De Paris
    Inventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
  • Patent number: 10918604
    Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 16, 2021
    Inventors: Ravikumar Nithiyanandam, Ganesh Vinayak Gat, Dinesh Kumar, Kamal S. Mehta, Premchand Dalichandji Nakhat, Vivek Jain, Priyank Sharma, Baibhav Joshi
  • Patent number: 10888519
    Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 12, 2021
    Inventors: Pankaj Soni, Premchand Dalichandji Nakhat, Ganesh Vinayak Gat, Kamal S. Mehta, Dinesh Kumar, Vikas Bali
  • Patent number: 10869839
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced Cmax, a Cmin:Cmax ratio of ?0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: December 22, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran- Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 10842760
    Abstract: A sustained-release preparation containing pseudoephedrine is provided comprising pseudoephedrine or a pharmaceutically acceptable salt thereof, and a hardened oil or stearic acid. The sustained-release preparation containing pseudoephedrine may contain a hardened oil or stearic acid in an amount of 100% by mass to 500% by mass with respect to the content of the pseudoephedrine or a pharmaceutically acceptable salt thereof. In addition, the sustained-release preparation containing pseudoephedrine may have a first part and a second part, the first part may contain the pseudoephedrine or a pharmaceutically acceptable salt thereof, and the first part or the second part may contain an optional active ingredient.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 24, 2020
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Yuki Nishikawa, Hiroaki Kikuoka, Michinori Oikawa, Hiroyuki Yamamoto, Tomoya Nakagawa
  • Patent number: 10842750
    Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 24, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Sebastian Schwier, Ulrike Bertram
  • Patent number: 10786489
    Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: September 29, 2020
    Assignee: Loxo Oncology Inc.
    Inventors: Mark Reynolds, Charles Todd Eary
  • Patent number: 10751272
    Abstract: Disclosed is a method of preparing a product composition comprising steps of: Preparing a mixture composition comprising a surfactant and a high melting point fatty compound and benefit agent; Separately preparing an aqueous base composition comprising an aqueous carrier and water soluble polymer, wherein the base composition is substantially free of a detersive surfactant selected from anionic surfactants, zwitterionic surfactant, amphoteric surfactant, and combinations thereof; Mixing the mixture composition and the aqueous base composition to form a discrete particle of the mixture composition dispersed in the aqueous base composition. Alternatively, the method comprises steps of preparing a discrete particle of the mixture composition; and mixing it with the aqueous composition.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 25, 2020
    Assignee: The Procter and Gamble Company
    Inventors: Junichi Yokogi, XinHao Zhu, Jorge Max Sunkel
  • Patent number: 10736909
    Abstract: The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be about 2.67 g/kg/day. A method for treating a neurological disorders is disclosed which involves administering trehalose to a subject as a single daily administration with a daily dose between about 0.25 to about 12.5 g/kg/day and in an embodiment of this method the daily dose is about 2.67 g/kg/day. Also disclosed herein is the use of trehalose in the manufacture of a medicament for treatment of neurological disorders, wherein the trehalose is formulated as a single daily dose with the trehalose present in the medicament in an amount of between about 0.25 to about 12.5 g/kg/day. In an embodiment the daily dose is about 2.67 g/kg/day.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: August 11, 2020
    Assignee: JUNAXO, INC.
    Inventors: Jonathan Michael Brotchie, Patrick Alexander Howson
  • Patent number: 10729653
    Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Serge Cuypers, Monique Berwaer, Domenico Fanara, Valery Barillaro
  • Patent number: 10695297
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 30, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sebastian Schwier, Marcel Haupts, Udo Rüttgers, Lutz Barnscheid, Jana Denker
  • Patent number: 10688053
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES, LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Patent number: 10668156
    Abstract: Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 2, 2020
    Assignee: BASF SE
    Inventors: Karl Kolter, Maximilian Angel, Matthias Karl, Silke Gebert, Michael Klemens Mueller
  • Patent number: 10668021
    Abstract: Provided are a metformin hydrochloride osmotic pump tablet and a preparation method therefor. According to the preparation method, a hetero-type stamping-prepared metformin hydrochloride tablet core is used, and a controlled-release coating is wrapped outside the stamped metformin hydrochloride tablet core, such that the metformin hydrochloride osmotic pump tablet is prepared.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 2, 2020
    Assignee: ELITE PHARMA TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Wu Tian, Qing Tian, Jianping Jiang
  • Patent number: 10668016
    Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: June 2, 2020
    Assignee: NanGenex Nanotechnology Incorporated
    Inventors: Réka Angi, Tamás Jordán, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10653663
    Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 19, 2020
    Assignee: DAE HWA PHARMA. CO., LTD.
    Inventors: In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Seul-Ae Lee, Han-Koo Lee
  • Patent number: 10646447
    Abstract: The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: May 12, 2020
    Assignee: GL PHARMTECH CORP.
    Inventors: Jun Sang Park, U-Hun Song, Ji-Yeon Sim
  • Patent number: 10639340
    Abstract: A method for drying to increase the useful life of botanicals and shorten the time to market after harvest of the botanicals. The method may include flash freezing the botanicals, at a desired optimal temperature range, soon after harvest. The method may include storing the frozen botanicals indefinitely prior to drying. The method may include drying the frozen botanicals using a lyophilizer at a desired optimal temperature and pressure.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 5, 2020
    Inventor: Eric Young
  • Patent number: 10638778
    Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 5, 2020
    Assignee: Pivot Pharmaceuticals US Inc.
    Inventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
  • Patent number: 10624888
    Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 21, 2020
    Assignee: SpecGX LLC
    Inventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
  • Patent number: 10603312
    Abstract: The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 31, 2020
    Assignee: Durect Corporation
    Inventors: Su Il Yum, Jaymin Shah, Sung Yun Kwon, Xiaoping Song